<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<ArticleSet>
  <Article>
    <Journal>
      <PublisherName>journal-jmsr</PublisherName>
      <JournalTitle>Journal of Medical and Surgical Research</JournalTitle>
      <PISSN>I</PISSN>
      <EISSN>S</EISSN>
      <Volume-Issue>Vol. VI, n 2</Volume-Issue>
      <PartNumber/>
      <IssueTopic>Multidisciplinary</IssueTopic>
      <IssueLanguage>English</IssueLanguage>
      <Season>December 2019</Season>
      <SpecialIssue>N</SpecialIssue>
      <SupplementaryIssue>N</SupplementaryIssue>
      <IssueOA>Y</IssueOA>
      <PubDate>
        <Year>-0001</Year>
        <Month>11</Month>
        <Day>30</Day>
      </PubDate>
      <ArticleType>JMSR Pathogens</ArticleType>
      <ArticleTitle>Susceptibility to Tigecycline of Multiresistant Bacteria at Ibn Rochd University Hospital-Casablanca</ArticleTitle>
      <SubTitle/>
      <ArticleLanguage>English</ArticleLanguage>
      <ArticleOA>Y</ArticleOA>
      <FirstPage>663</FirstPage>
      <LastPage>666</LastPage>
      <AuthorList>
        <Author>
          <FirstName>Assiya El</FirstName>
          <LastName>Kettani</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>N</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Soufiane</FirstName>
          <LastName>Arji</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Fakhreddine</FirstName>
          <LastName>Maaloum</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Khalid</FirstName>
          <LastName>Katfy</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Khalid</FirstName>
          <LastName>Zerouali</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Houria</FirstName>
          <LastName>Belabbes</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Naima</FirstName>
          <LastName>Elmdaghri</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
        </Author>
      </AuthorList>
      <DOI/>
      <Abstract>A descriptive prospective study was conducted between 2015 and 2017 at the Microbiology laboratory of the Casablanca University Hospital Center to study the Tigecycline susceptibility of isolated multi drug resistant bacteria (MDRB): Imipenem-resistant Acinetobacter baumannii (IRAB), ESBL+/- Carbapenemase -producing enterobacteria (ESBLE), Meticillin-resistant Staphylococcus aureus (MRSA) and Vancomycin-resistant Enterococci (VRE). Antibiotic sensitivity tests were performed by diffusion method and those for Tigecycline by E-test strips according to EUCAST / CA-SFM. Breakpoints of interpretation of Tigecycline sensitivity were according to the FDA. A total of 692 MDRB strains were studied. The tigecycline resistance rate was 33.9% (25.3% I, 8.6% R). For IRAB, it was 46% (30.5% I, 15.5% R), for ESBLE 27.9% (100% I), for MRSA 10% (100% R) and no VRE was resistant to Tigecycline. However, as EUCAST has not determined breakpoints for the in vitro thresholds of A.baumannii concerning Tigecycline, conclusions should not be formally established as to its sensibility.</Abstract>
      <AbstractLanguage>English</AbstractLanguage>
      <Keywords>Multi-resistant bacteria, Sensibility, Tigecycline</Keywords>
      <URLs>
        <Abstract>https://journal-jmsr.net/ubijournal-v1copy/journals/abstract.php?article_id=6730&amp;title=Susceptibility to Tigecycline of Multiresistant Bacteria at Ibn Rochd University Hospital-Casablanca</Abstract>
      </URLs>
      <References>
        <ReferencesarticleTitle>References</ReferencesarticleTitle>
        <ReferencesfirstPage>16</ReferencesfirstPage>
        <ReferenceslastPage>19</ReferenceslastPage>
        <References>[1] Vergidis PI, Falagas ME. Multidrug-resistant Gram-negative bacterial infections: the emerging threat and potential novel treatment options. Curr Opin Investig Drugs 2008; 9: 176–83&#13;
&#13;
[2] Norskov-Lauritsen N, Marchandin H, Dowzicky MJ. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2007–2007). Int J Antimicrob Agents 2009; 34:121–30.&#13;
&#13;
[3] Tygacil Package Insert (2014), Wyeth Pharmaceuticals, Philadelphia, PA; 2014. Available at: www.tygacil.com. Accessed July, 2014&#13;
&#13;
[4] Marchaim D, Pogue JM, Tzuman O, Hayakawa K, Lephart PR, Salimnia H et al. Major variation in MICs of tigecycline in Gram-negative bacilli as a function of testing method. J Clin Microbiol. 2014;52(5):1617–1621&#13;
&#13;
[5] Yang Q, Xu YC, Kiratisin P, Dowzicky MJ. Antimicrobial activity among Gram-positive and Gram negative organisms collected from the Asia-Pacific region as part of the Tigecycline Evaluation and Surveillance Trial: Comparison of 2015 results with previous years. Diagn Microbiol Infect Dis. 2017;89(4):314-323&#13;
&#13;
[6] Froment Gomis P, Jean-Pierre H, Rousseau-Didelot M.N, Compan B, Michon A L, Godreuil S, Tigecycline : CMI 50/90 vis-and;agrave;-vis de 1766 bacilles a Gram-nand;eacute;gatif (entand;eacute;robactand;eacute;ries rand;eacute;sistantes aux cand;eacute;phalosporines de troisiand;egrave;me gand;eacute;nand;eacute;ration), Acinetobacter baumannii et Bactand;eacute;rioses du groupe fragilis, CHU – Montpellier, 2008–2011. Pathol Biol 2013 ; (61) :282–285&#13;
&#13;
[7] Bris, G. Auger, F. Kowalczyk, M. Eveillard, M.-L. Joly-Guillou. Activitand;eacute; in vitro de la tigecycline vis-and;agrave;-vis de 760 souches bactand;eacute;riennes isoland;eacute;es au CHU d’Angers–le programme TEST 2006–2009. Pathol Biol 2012 ; 60 :336–339&#13;
&#13;
[8] Marco F, Dowzicky M J. Antimicrobial susceptibility among important pathogens collected as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) in Spain, 2004–2014. J Glob Antimicrob Resist 2016 (6):50–56&#13;
&#13;
[9] Paluchowska P , Nowak P , Skalkowska M , Bjdak A . Evaluation Of In Vitro Tigecycline Activity Against Multidrug-Resistant Acinetobacter Baumannii Clinical Isolates From Poland. Acta Pol Pharm 2017, 74(3):793-800&#13;
&#13;
[10] Piewngam P, Kirastisin P. comparative assessment of antimicrobial susceptibility testing for tigecycline and colistin against Acinetobacter baumannii clinical isolates, including multidrug-resistant isolates. Int J Antimicrob Agents. 2014 ;44(5):396-401.&#13;
&#13;
[11] Seputiene V, Povilonis J, Armalyte J, Suziedelis K, Pavilonis A, Suziedeliene E. Tigecycline—how powerful is it in the fight against antibiotic-resistant bacteria? Medicina (Kaunas) 2010;46:240–8.</References>
      </References>
    </Journal>
  </Article>
</ArticleSet>